Gevaert and his team (41) found that using anti-IL-5 treatment in patients with CRS with nasal polyps (CRSwNP) reduces eosinophilic infiltration, thereby reducing the size of nasal polyps. The gene discussed is IL5; the disease is nasal cavity polyp.